Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04727723
Other study ID # CAAA601A0IT02
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 9, 2021
Est. completion date April 1, 2025

Study information

Verified date July 2023
Source Advanced Accelerator Applications
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.


Description:

Data on patients will be collected from the date when patient consent was obtained, during treatment with Lutathera® and for a follow-up period until end of study (EOS), defined as the time when the last enrolled patient has completed 36 months of assessments (unless early termination) after enrolment. Data will be collected in accordance with routine clinical visits. The study duration will be 48 months in total: 12 months recruitment and 36 of follow-up from the last patient in.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 164
Est. completion date April 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Written informed consent must be obtained prior to any data collection. - Patients must be diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic-neuroendocrine tumour (GEP-NET). - Aged =18 years. - Patients must be naïve to treatment with Lutathera® at enrolment. Exclusion Criteria: - Participation in a current or prior investigational study within 30 days preceding enrolment or within 5 half-lives of the investigational product, whichever is longer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lutathera®
Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.

Locations

Country Name City State
Italy Novartis Investigative Site Alessandria
Italy Novartis Investigative Site Bologna
Italy Novartis Investigative Site Brescia
Italy Novartis Investigative Site Cona
Italy Novartis Investigative Site Firenze
Italy Novartis Investigative Site Latina
Italy Novartis Investigative Site Meldola
Italy Novartis Investigative Site Messina
Italy Novartis Investigative Site Milano
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Negrar
Italy Novartis Investigative Site Padova
Italy Novartis Investigative Site Pisa
Italy Novartis Investigative Site Reggio Emilia
Italy Novartis Investigative Site Rionero In Volture
Italy Novartis Investigative Site Roma
Italy Novartis Investigative Site Rozzano
Italy Novartis Investigative Site Torino

Sponsors (1)

Lead Sponsor Collaborator
Advanced Accelerator Applications

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) PFS, defined as the time, in months, from Lutathera® treatment initiation to the date of first objective tumour progression, determined according to Response Evaluation Criteria in Solid Tumours (RECIST) Criteria, Version 1.1, or death due to any cause, whichever comes first. Up to 48 months
Secondary Objective Response Rate (ORR) ORR, defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1 Up to 48 months
Secondary Duration of Response (DoR), for those patients who achieve a best response of PR or better DoR, defined as the time, in months, from the date when criteria for response are first met until the date of a progression event (according to the primary definition of PFS). Up to 48 months
Secondary Clinical Benefit Rate (CBR) CBR, defined as the proportion of treated patients who achieve a best overall response of stable disease (SD), PR or CR according to RECIST 1.1. Up to 48 months
Secondary Duration of Clinical Benefit, for those patients who achieve a best response of SD or better Duration of clinical benefit, defined as the time, in months, from the date when criteria for clinical benefit are first met until the date of a progression event (according to the primary definition of PFS). Up to 48 months
Secondary Time to Progression (TTP) TTP, defined as the time, in months, from Lutathera® treatment initiation to the date of first objective tumour progression, assessed according to RECIST 1.1. Up to 48 months
Secondary Assess the impact of treatment on health-related Quality of Life (HRQoL) by EORTC QLQ-C30 questionnaire EORTC QLQ-C30 will be filled in by the patient prior to knowing computed tomography (CT) scan/magnetic resonance imaging (MRI) result.
The EORTC QLQ-C30 questionnaire is designed for use with a wide range of cancer patient populations and is intended to be supplemented by tumour-specific questionnaire modules. The EORTC QLQ-C30 incorporates different multi-item scales, i.e. functional scales, symptom scales and a Global Health Status/QoL scale. All parameters are evaluated using single or multi-item questions which are consequently converted into a 100-point score.
Up to 48 months
Secondary Assess the impact of treatment on health-related Quality of Life (HRQoL) by EORTC QLQ-G.I.NET-21 questionnaire EORTC QLQG. I.NET-21 will be filled in by the patient prior to knowing computed tomography (CT) scan/magnetic resonance imaging (MRI) result.
EORTC QLQ-G.I.NET-21 questionnaire is a module specific for neuroendocrine tumours and comprises 21 questions assessing disease symptoms, side effects of treatment, body image, disease related worries, social functioning, communication and sexuality. Each subscale is based on the following items: endocrine scale (items 31-33); gastrointestinal scale (34-38); treatment scale (39, 40, and 46); social function scale (42, 44, and 49); disease related worries scale (41, 43, and 47); muscle/bone pain (48), sexual function (51), information/communication function (50), and body image (45).
All parameters are evaluated using single or multi-item questions which are consequently converted into a 100-point score
Up to 48 months
Secondary Time to Deterioration (TTD) in global health scale (TTD- global health scale) TTD, defined as the time, in months, from Lutathera® treatment initiation to the date of first deterioration of =10 points in the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 global health scale score compared to the baseline score for the same domain. Baseline, up to 48 months
Secondary Time to Deterioration (TTD) in diarrhoea item (TTD- diarrhoea item) TTD, defined as the time, in months, from Lutathera® treatment initiation to the date of first deterioration of =10 points in the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 diarrhoea item score compared to the baseline score for the same domain. Baseline, up to 48 months
Secondary Time to Deterioration (TTD) in fatigue item (TTD- fatigue item) TTD, defined as the time, in months, from Lutathera® treatment initiation to the date of first deterioration of =10 points in the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 fatigue item score compared to the baseline score for the same domain. Baseline, up to 48 months
Secondary Time to Deterioration (TTD) in pain item (TTD- pain item) TTD, defined as the time, in months, from Lutathera® treatment initiation to the date of first deterioration of =10 points in the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 pain item score compared to the baseline score for the same domain. Baseline, up to 48 months
Secondary Number of patients with Adverse Events (AEs) related to study drug Number of patients with Adverse Events (AEs) related to study drug will be reported Up to 48 months
Secondary Seriousness and relationship to Lutathera® treatment Seriousness and relationship to Lutathera® treatment will be reported Up to 48 months
Secondary Incidence of deaths due to any cause. Incidence of deaths due to any cause will be reported Up to 48 months
Secondary Number of participants with notable changes in laboratory parameters Safety measured by the notable post-baseline changes in laboratory parameters compared to baseline.
Standard Lab parameters will be reported when performed as clinical practice.
Up to 48 months
Secondary Number of participants with notable changes in physical examination Safety measured by the notable post-baseline changes in physical examination compared to baseline.
Physical examination will be reported when performed as clinical practice.
Up to 48 months
Secondary Number of participants with notable changes in vital signs Safety measured by the notable post-baseline changes in vital signs compared to baseline.
Vital signs will be reported when performed as clinical practice.
Up to 48 months
Secondary Number of participants with notable changes in electrocardiogram (ECG) Safety measured by the notable post-baseline changes in ECG compared to baseline.
ECG results will be reported when performed as clinical practice.
Up to 48 months
Secondary Changes in Karnofsky Performance Status (KPS) scores KPS scores will be reported when performed as clinical practice. Karnofsky Performance Status (KPS) is a standard way of measuring the ability of cancer patients to perform ordinary tasks. The KPS score ranges from 0 to 100. A higher score means the patient is better able to carry out daily activities. KPS forms must be completed by the treating physician at each treatment and follow-up visit. Up to 48 months
Secondary Baseline characteristics of patients selected Baseline characteristics of patients prescribed with Lutathera® (medical and disease history, prior treatments for NETs, baseline and demographic characteristics). Baseline
Secondary Correlation of possible prognostic factors with clinical effectiveness outcomes. Potential prognostic factors (e.g., somatostatin receptor (SSTR) expression levels (tumour uptake score) determined by Octreoscan® scintigraphy or 68Ga PET/CT according to clinical practice, standardized uptake value (SUV) of [18F]fluorodeoxyglucose (FDG) PET/CT (if performed), levels of the biomarkers collected in clinical routine, stage of disease at the time of first diagnosis, KPS score at baseline). Up to 48 months
Secondary Describe radiation emission levels at one metre distance of patients treated Radiation emission levels at one metre distance of patients treated with Lutathera® at the time of hospital discharge and as collected according to the local Summary of Product Characteristics (SmPC), the "Scheda di Monitoraggio AIFA" and as per clinical practice Up to 18 months
Secondary Describe dosimetry data after administration (if dosimetry is performed) Number of patients undergoing dosimetry, dosimetry method used and radiation-absorbed doses to tumour and normal organs after Lutathera® administration. Up to 18 months
Secondary Number of days of hospitalization for Lutathera® treatment. Number of days of hospitalization for Lutathera® treatment will be provided Up to 18 months
Secondary Frequency of hospitalization. Frequency of hospitalizations will be provided Up to 48 months
Secondary Duration of hospitalization Duration of hospitalizations will be provided Up to 48 months
Secondary Extent of usage of concomitant medications for AE treatment. Extent of usage of concomitant medications for AE treatment will be provided Up to 48 months
Secondary Changes in use of concomitant medications for symptoms management Changes in use of concomitant medications for symptoms management will be provided Up to 48 months
Secondary Information about the patient's diagnosis-related group (DRG) Information about the patient's diagnosis-related group (DRG) will be provided Up to 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT06155318 - 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Terminated NCT01994213 - A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Phase 2
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Completed NCT04852679 - Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs Phase 3
Enrolling by invitation NCT05064150 - Neuroendocrine Tumors - Patient Reported Outcomes
Recruiting NCT06256705 - Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort N/A
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Recruiting NCT04609592 - Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Phase 1
Recruiting NCT05701241 - Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Phase 4
Completed NCT02948946 - Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT04986085 - Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruiting NCT05262556 - NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas Phase 1
Completed NCT03017690 - Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)